ONC201 Looks to Prove Efficacy in Trial For Rare H3K27M-Muta

The dopamine receptor D2 antagonist ONC201 is under evaluation in patients with H3K27M-mutated diffuse midline glioma in the phase 3 ACTION trial.

Related Keywords

North Carolina , United States , University Of Pennsylvania , Pennsylvania , University Of North Carolina , Philadelphia , Charlotte , Stephen Bagley , Ashley Sumrall , Hospital Of The University Pennsylvania , University Of North Carolina Chapel Hill , Abramson Cancer Center , Atrium Health Carolinas Medical Center , Atrium Health Levine Cancer Institute , Internal Medicine , Medical Oncology , North Carolina Chapel Hill , Phase Studies Pave , Data Shows Tolerable Safety Profile , Onc201 , Patients With H3k27m Mutated Diffuse Midline Glioma , Action Trial , Nct05580562 , D , Osce , Naacp , The Hospital Of University Pennsylvania ,